-
To stay updated on the relevant developments, make sure you are signed up for our newsletter.
Topics
Meeting category
Program Language
English
Organizer
International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases
General
What's New
Welcome
With more than 100 monoclonal antibiotics (mAbs) in use, harnessing this technology has advanced therapeutic development for COVID-19 and underscored their utility and versatility to respond rapidly to emerging global health threats.
Recent approvals and recommendations for mAbs in preventing and treating RSV and Ebola offer novel tools to control these (re) emerging viruses.
They also offer new avenues for preventing bacterial and parasitic infections, such as Clostridium difficile and Plasmodium falciparum (causative agent of malaria tropica in humans).
Those advances come hand-in-hand with educational needs to comprehend technology, pharmacological properties, challenges for equitable access, and recent clinical data.
In contrast to existing programs, this workshop provides a platform for cross-disciplinary discussion, catalyzes knowledge transfer, and prompts discussions on remaining unknowns to ultimately move the field forward.
Program Directors
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Daniel Kuritzkes, MD
Brigham and Women's Hospital; Harvard Medical School, United States
General Information
Uniques Features
Who Should Attend?
Meeting Objectives
Learning Objectives
Practical Information
Certificate of Attendance
Language
Enduring Materials
Disclaimer
Liability and Insurance
Photographs, Audio, and Video Recording
Code of Conduct
Registration
Program
Committees
Support
Previous Editions
Language
Related Programs
